The National Lung Cancer Screening Trial (NLST) demonstrated the use of LDCT scans for lung cancer screening. However, the NLST was implemented in urban hospitals and prior to the Lung CT Screening Reporting and Data System (Lung-RADS).
Introduction
Lung cancer is the leading cause of cancer related mortality in the United States, accounting for 1 in 4 cancer related mortalities. 1 Kentucky has the highest incidence of lung cancer in the country at 91.4 per 100,000 compared to the national rate of 58.3 per 100,000. 2 Furthermore, Appalachian Kentucky counties have an even higher incidence rate of lung cancer, at 107.2 per 100,000. According to the Appalachian Regional Commission, the majority of Kentucky's Appalachian counties are under significant economic distress, which has been associated with overall poor health. 3, 4 The Appalachian region has been identified as a medically underserved region due to the financial, geographic, and health system challenges in the region. 5 While there have been tremendous strides in screening for other types of cancers, such as colon, prostate, and cervical, lung cancer screening still remains an https://doi.org/10.1017/cts.2019.416 Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 14 Sep 2019 at 03:48:55, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. area of controversy. The National Lung Screening Trial (NLST) was a large, multicenter, randomized controlled trial that compared annual low dose helical computed tomography (LDCT) to chest x-ray in high risk individuals as a tool for lung cancer screening. 6, 7 The NLST demonstrated a statistically significant improvement in survival with annual LDCT in individuals who are high risk for lung cancer. However, because site selection for the study was among 33 urban or metropolitan institutions across the country, the feasibility of implementing a screening program similar to NLST in a rural population, similar to the population present in Appalachian Kentucky, is unknown.
Moreover, the positive predictive value of diagnostic and screening tests are dependent on the disease incidence of the population in which it is used. 8 Thus, the impact of LDCT screening in a region with high rates of lung cancer may be under-represented.
Additionally, the NLST was conducted prior to the advent of Lung CT Screening Reporting and Data System (Lung-RADS). 9 Lung-RADS is an effort by the American College of Radiology (ACR) to standardize reporting of the screening LDCT results based on lung cancer risk. Lung-RADS categorizes the imaging finding of a screening LDCT from 0 to 4. As the number increases, higher the likelihood of malignancy. Based on categorization of the imaging findings, the Lung-RADS guidelines recommend additional imaging and diagnostic testing to be performed to confirm the diagnosis. 9 Retrospective application of the Lung-RADS criteria to the NLST results showed a potential reduction in the false positive rate, but also a decrease in sensitivity. 10 the number of subsequent testing after baseline LDCTs, and the number of cancers identified and to compare these results to NLST baseline data.
Methods

Lung Cancer Screening Program
St. Claire Healthcare (SCR) is a 159-bed community hospital in NE Kentucky and is registered with ACR to perform lung cancer screening. SCR provides healthcare services to 11 counties in northeastern Kentucky, all of which are rural counties, with a total population of 166,130 people served. Their lung cancer screening program commenced in 2015 and includes trained on-site radiologists who read all LDCTs and a data manager to ensure all data is entered into the ACR system. Annual reminders are sent out to patients by the radiology suite but shared decision-making and tobacco cessation must be performed and documented by the ordering provider, which is verified by radiology. All readings follow the ACR Lung-RADS reporting criteria and data is uploaded into the SCR ACR database for tracking and monitoring purposes. according to management recommendations and probability of malignancy, which resulted in three categories: 1/2, 3, 4A/4B/4X. To compare our results to the Pinsky et al results, we also collapsed the Lung-RADS results from our study into the same categories. Some readings in the NLST had more than one category findings (example 3 and 4B). For these cases, we attributed their count to the category with the greatest probability of malignancy.
Data collection and outcome
We further assessed the number of subsequent testing till diagnosis (if any), ranging from additional imaging to resections performed based on the findings of the LDCT, and calculated the percentage that resulted in a cancer diagnosis. SCR results were then compared to NLST baseline LDCT results and number of subsequent testing and cancer diagnoses. Subsequent testing in our study included follow-up imaging, biopsies, or any other procedures and the definition was mirrored as it was described in the NLST study. All study procedures were approved by the University of Kentucky and St. Claire Regional Medical Center Institutional Review Boards.
Results
There were a total of 774 SCR patients who received a baseline LDCT for lung cancer screening between August of 2015 and August of 2018. (Table 1) The mean age at the time of the LDCT was 63 ± 6 years. The patients were 49.9% female and 91.2%
were white, which represents the general Appalachia population. The mean pack years smoked was 54, with a standard deviation of 29 pack years. 69%% of patients were current smokers and the remainder were former smokers who quit less than or equal to 6 Among baseline SCR LDCT readings 85.2% were categorized as Lung-RADs 1 or 2, 8.0% as Lung-RADs 3, and 6.7% as Lung-RADs 4A, 4B, or 4X. (Table 2) In terms of subsequent testing and cancer diagnoses, we found 84 patients (10.9%) had further testing performed at SCR compared to 24.2% in the NLST study (Table 3) . Majority of those who had subsequent testing had non-invasive testing. 18 (2.3%) of the 774 SCR patients screened were ultimately diagnosed with a lung malignancy compared to only 1.1% in the NLST study. More importantly, among SCR patients who had subsequent testing (n=84), 21.4% were diagnosed with cancer compared to 4.6% in the NLST study who had subsequent testing.
Discussion
Controversy surrounded the announcement of the lung screening guideline when published by the United State Preventive Services Task Force. 11 The concern for high false-positives rates and having a guideline based on evidence from one large multi- compared to the NLST. The rates of cancer identified at SCR can also be attributable to the fact that the prevalence of lung cancer is highest in Eastern Kentucky compared to the rest of the United States. This is an important factor when determining the value of LDCT screening in populations with high risk of developing lung cancer. Overall, lung cancers identified through LCS in Eastern Kentucky was double (2.3%) compared to the NLST study (1.1%). 6 We also found higher rates of lung cancer from screening compared to a multisite implementation study in the Veterans Administration (VA) system. This VA study identified 56.2% of the patients screened needed additional tracking, while lung cancer was eventually found in only 1.5% of the study population. 14 The NLST was conducted across urban and metropolitan sites. The infrastructure, resources, and access are different in rural communities. A secondary aim of this study was to evaluate the feasibility of implementing LDCT screening guidelines in a rural community. We sought to assess whether subsequent testing rates would be higher compared to the NLST study. In fact, SCR conducted fewer subsequent tests compared to both the NLST study and VA system study. 7, 10, 14 Since tracking of results and repeat testing over time drives fear, anxiety and concern among patients, the importance of reducing un-necessary testing cannot be emphasized enough. When we compared the number of cancers identified among those who had subsequent testing after their baseline LCS, SCR identified more cancers (21.4%) compared to those with subsequent testing in the NLST study (4.6%). To our knowledge, this is the first study to demonstrate that.
There are limitations in our study that should be noted. While we compared SCR screening outcomes to a study that applied the Lung-RADs criteria post-hoc to the NLST study, there could be significant differences in false positive rates and subsequent testing rates if the Lung-RADs was actually applied during the NLST a priori. Nonetheless, the intention of our study was to demonstrate the difference of subsequent testing rates with the application of Lung RADs criteria at the time of LCS screening compared to the NLST study, which lacked such criteria. Another limitation is that we conducted the study in a region of the country with the highest rates of lung cancer. 2 This impacts the positive and negative predictive value of LDCT in screening for lung cancer. 8 Conversely, this finding has important policy and health system implications when the value of implementing a LCS program is being considered. This is especially important in rural areas where resource allocation is a critical decision factor as overall resources are limited. Finally, we cannot generalize our findings beyond that of SCR, as LCS programs can have significant variability. This was also found in closed systems with multiple sites, such as the VA system. 14 studies must be replicated in other rural regions in the United States with varying incidence rates of lung cancer.
We conclude that the application of the Lung-RADS has the potential to reduce unnecessary testing; and when testing is warranted, a higher rate of lung cancers can be identified. Further research is needed to assess whether these findings are replicable in other rural regions where lung cancer is comparable to national rates. 
